Lilly/Glycomed research agreement
Glycomed signed a three-year agreement with Lilly to discover and develop new therapies for the cardiovascular disease, vascular restonosis. Lilly will fund a drug discovery program at Glycomed and conduct R&D efforts at Lilly Research Labs. Lilly retains the rights to produce and market products resulting from research. Glycomed researches complex carbohydrates for development of new drugs. In addition, Lilly has acquired a 10% equity stake in the privately held, Alameda, California-based firm.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.